AbbVie
Corporate Bias Rating
Expand Summary
Risk Level:
Summary:
Abbvie is High Risk. The company yields to political activism in shaping corporate governance, potentially alienating consumers, dividing employees, and harming shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Abbvie embraces corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach fails to safeguard free exercise, free speech, and free enterprise.
View Full Corporate Bias Ratings ReportBoard Bias
Expand Summary
CEO of AbbVie
Richard A. Gonzalez
Summary:
Headquartered in Chicago, Illinois, AbbVie is a member of the Fortune 250 operating in the Pharmaceuticals Biotechnology and Life Sciences industry. Richard A. Gonzalez serves as CEO/President and Chairman, leading the company’s C-suite executive team and the board of directors. Amongst these teams, the collective leadership is responsible for $101,550 to Republican causes and $84,950 to Democratic causes. Under their tenure, AbbVie currently holds a 'High Risk' risk rating.
View Full Board Bias ReportPolitical Contributions of Leadership:
$101,550
$84,950
Republican
Democrat
China Risk Database
Expand Summary
Total Estimated Sanctions (3-year Avg.)
$169,620,585
Average Annual Revenue
Global
$45,537,000,000
China Revenue
1.12%
$511,666,667
Annual Average of Total Assets
Global
$116,240,666,667
China Assets
1.15%
$1,334,750,301
Shareholder Proposals
Expand Summary
| Date | ESG Category | Proponent | Summary of Resolution | Mgmt Rec | Total Vote % in Favor |
|---|---|---|---|---|---|
| 5/3/24 | Zevin Asset Management on behalf of Alyson Pyette | Stockholder Proposal on Lobbying | Against | N/A | |
| 5/3/24 | Friends Fiduciary Corporation and Co-filers Mercy Investment Services | Stockholder Proposal on Patent Process | Against | N/A | |
| 5/3/24 | John Chevedden on behalf of Kenneth Steiner | Simple Majority Vote | Against | N/A | |
| 5/5/23 | Governance | John Chevedden | Simple Majority Voting | Against | 53.90% |
| 5/5/23 | Governance | Dana Investment Advisers | Issue a Report on Lobbying | Against | 35.70% |
| 5/5/23 | Governance | Friends Fiduciary Corporation | Issue a Report on Patent Process | Against | 29.00% |
| 5/5/23 | Governance | As You Sow | Report on Political Spending | Against | 14.90% |
| 5/6/22 | Governance | Kenneth Steiner | Shareholder Ratification of Termination Pay Exceeding 2.99x Total Pay | Against | 50.10% |
| 5/6/22 | Social | As You Sow | Report on Political Spending | Against | 39.32% |
| 5/6/22 | Governance | Friends Fiduciary Corp. | Board Oversight of Risks Related to Anticompetitive Practices | Against | 32.82% |
| 5/6/22 | Governance | Rhode Island Employees Retirement System | Independent Board Chair | Against | 30.18% |
In the News
Expand Summary
AbbVie , Amgen , Bank of America , Caterpillar , Citigroup , Citizens Financial , Coca-Cola , Colgate-Palmolive , CVS Health , Delta Air Lines , General Motors , JPMorgan Chase , Morgan Stanley , Prudential Financial , Robert Half , Sherwin-Williams , Uber Technologies , UPS , Wells Fargo